CG Oncology reports 68% cut in bladder cancer recurrence risk in Phase 3 trial
CG Oncology announced that its oncolytic immunotherapy cretostimogene reduced the risk of non‑muscle invasive bladder cancer recurrence by 68% in the pivotal PIVOT‑006 Phase 3 trial. The study enrolled 367 patients across the United States and Canada and met its primary endpoint with a hazard ratio of 0.32. The company said it will file a broadened biologics licence application in the second quarter of 2027 and a separate BCG‑unresponsive filing by March 2027.
Why it matters
The company expects the data to support a broader regulatory filing, which could expand the drug’s market beyond the original BCG‑unresponsive indication (the company says). Analysts note the result could widen the potential market for cretostimogene (the company says).
Key facts
- 1The Phase 3 PIVOT‑006 trial enrolled 367 patients at roughly 90 sites in the United States and Canada. clinicaltrialsarena.com
- 2Cretostimogene reduced bladder cancer recurrence risk by 68% versus the control arm, with a hazard ratio of 0.32. clinicaltrialsarena.com
- 3Median follow‑up was 17 months as of 26 October 2026. clinicaltrialsarena.com
- 4The trial met its primary endpoint and showed statistically significant improvement in recurrence‑free survival (p‑value < 0.0001). finance.yahoo.com
- 5CG Oncology plans to submit a broadened BLA in Q2 2027 and a separate BCG‑unresponsive BLA by the end of March 2027. finance.yahoo.com
- 6Shares rose 23.7% in pre‑market trading, opening at $92 versus $74.40 at the prior close. clinicaltrialsarena.com
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.